Lead Product(s): Multi-specific antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 07, 2020
The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA).